Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says

Martin Shkreli—the ex-pharmaceutical executive infamous for illegally hiking the price of a lifesaving anti-parasitic drug by more than 4,000 percent and getting a seven-year prison sentence for the fraudulent scheme he used to do it—has been under a lifetime ban from the pharmaceutical industry since 2022.

马丁·什克雷利（Martin Shkreli）曾是一位制药公司高管，因非法将一种救命抗寄生虫药物的价格提高了4000%以上，并因实施该欺诈计划被判处七年监禁而臭名昭著。自2022年以来，他一直受到制药行业的终身禁令限制。

However, according to the Federal Trade Commission and the attorneys general of seven states, Shkreli has “flagrantly and repeatedly” violated that ban nearly the entire time—allegedly by trading stock in dozens of drug companies and discussing the industry during livestreams on social media.

然而，据美国联邦贸易委员会（FTC）和七个州的司法部长称，什克雷利几乎在整个期间都“公然且反复地”违反了该禁令——据称他通过交易数十家制药公司的股票，并在社交媒体的直播中讨论该行业来实施违规行为。

On Tuesday, the FTC and the seven states asked a federal judge to hold Shkreli in contempt for the alleged violations. The states include New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same states that joined the FTC in suing Shkreli in 2020 over the “elaborate anticompetitive scheme” involving the anti-parasitic drug, Daraprim.

周二，FTC和这七个州请求联邦法官以涉嫌违规为由，裁定什克雷利藐视法庭。这些州包括纽约州、加利福尼亚州、伊利诺伊州、北卡罗来纳州、俄亥俄州、宾夕法尼亚州和弗吉尼亚州——这些州曾在2020年与FTC联手起诉什克雷利，指控其涉及抗寄生虫药物“达拉匹林”（Daraprim）的“精心策划的反竞争计划”。

The scheme raised the price from $17.50 per pill to $750 per pill virtually overnight, while blocking generic competitors from entering the market.

该计划几乎在一夜之间将每片药的价格从17.50美元提高到了750美元，同时阻止了仿制药竞争对手进入市场。

In 2022, the federal court recognized the “seriousness” of issuing such a lifetime industry ban, but ruled that “Shkreli’s egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct warrants imposition of an injunction of this scope.”

2022年，联邦法院承认发布此类行业终身禁令的“严重性”，但裁定“什克雷利恶劣、蓄意、反复、长期且最终危险的非法行为，有必要实施此范围的禁令。”

The ban, among many things, “explicitly prohibits” Shkreli from owning stock in pharmaceutical companies and making public statements that could influence a pharmaceutical company’s business, according to the FTC and the states.

据FTC和各州称，该禁令除其他事项外，“明确禁止”什克雷利持有制药公司股票，并禁止他发表可能影响制药公司业务的公开声明。

With the alleged violations, the FTC and the states are now seeking to force Shkreli to divest from all pharmaceutical companies and pay a fine equal to his profits from trading pharmaceutical company stocks. They also want the court to lay out “clear and escalating consequences” if Shkreli violates the ban in the future, including further financial penalties and incarceration.

鉴于这些涉嫌违规的行为，FTC和各州目前正寻求强制什克雷利从所有制药公司撤资，并支付相当于其交易制药公司股票所得利润的罚款。他们还希望法院明确规定，如果什克雷利未来再次违反禁令，将面临“明确且递增的后果”，包括进一步的经济处罚和监禁。

“The extensive record compiled by FTC staff shows that Mr. Shkreli chose to blatantly disregard the order after leaving prison,” FTC Commissioner Mark Meador said in a statement. “Among other actions, he has traded pharmaceutical stocks and actively sought to influence the business and management of multiple pharmaceutical companies through public commentary, in violation of the terms of the injunction. … A lifetime industry ban is only effective if breaches are met with consequences commensurate with the seriousness of the order.”

FTC委员马克·米多（Mark Meador）在一份声明中表示：“FTC工作人员汇编的大量记录显示，什克雷利先生在出狱后选择公然无视该命令。除其他行为外，他交易了制药公司股票，并通过公开评论积极寻求影响多家制药公司的业务和管理，这违反了禁令条款……只有当违规行为受到与命令严重性相称的惩罚时，行业终身禁令才有效。”

In a response, Shkreli said he was surprised by the FTC’s filing. “I could see totalitarian NY AG Letitia James trying to limit a citizen’s free speech but not from Trump’s FTC,” he wrote on social media.

作为回应，什克雷利表示他对FTC的起诉感到惊讶。他在社交媒体上写道：“我能理解极权主义的纽约州总检察长莱蒂西亚·詹姆斯（Letitia James）试图限制公民的言论自由，但没想到特朗普领导下的FTC也会这样做。”

The brief filed by the FTC and the states breaks down Shkreli’s alleged violations in four phases: (1) a 2022 trading competition with another YouTuber; (2) shorting a small biotech firm in 2024, along with trading in other Pharmaceutical Company stocks; (3) a 2025 trading challenge in which he shorted three small biotech firms along with trading in many other Pharmaceutical Company stocks; and (4) a trading challenge begun in June 2026 with a $10,000,000 account in which he is again trading in Pharmaceutical Company stocks.

FTC和各州提交的简报将什克雷利的涉嫌违规行为分为四个阶段：（1）2022年与另一位YouTube博主的交易竞赛；（2）2024年做空一家小型生物技术公司，并交易其他制药公司股票；（3）2025年的交易挑战，期间他做空了三家小型生物技术公司，并交易了许多其他制药公司股票；以及（4）2026年6月开始的一项交易挑战，他使用一个1000万美元的账户再次交易制药公司股票。

In numerous livestreams on various social media platforms, Shkreli would sometimes show his accounts on screen, the filing said. He discussed pharmaceutical companies at length, evaluating stocks and predicting the outcomes of pivotal clinical trials.

文件称，在各种社交媒体平台的多次直播中，什克雷利有时会在屏幕上展示他的账户。他详细讨论了制药公司，评估股票并预测关键临床试验的结果。

In 2025, he told his viewers about his “magic trick,” saying: “It doesn’t matter what trades I make because I can always find a couple of biotech stocks to smoke.” Later in the year, Shkreli advised his viewers to short one pharmaceutical company’s stock, and the company’s stock price quickly dropped 17 percent.

2025年，他向观众讲述了他的“魔术”，说道：“我做什么交易并不重要，因为我总能找到几只生物技术股票来‘干掉’。”同年晚些时候，什克雷利建议观众做空一家制药公司的股票，随后该公司股价迅速下跌了17%。

The FTC and the states wrote in their filing that the stocks Shkreli discussed in livestreams are “likely the tip of the iceberg.” FTC staff only reviewed a fraction of Shkreli’s social media activity, and Shkreli has made several references to other accounts he has. “I have some other accounts that I’[d] show you, but, like, I know feds are watching, so f[*]ck that,” he said, according to the filing.

FTC和各州在文件中写道，什克雷利在直播中讨论的股票“很可能只是冰山一角”。FTC工作人员仅审查了什克雷利社交媒体活动的一小部分，而什克雷利曾多次提到他拥有的其他账户。据文件记载，他说：“我还有一些其他账户可以展示给你们看，但是，我知道联邦政府在盯着，所以去他的吧。”